Yung Zip Chemical Ind. Co., Ltd. · TPEX:4102
Yung Zip Chemical Ind — 2025 Investors Conference
22 slides from Yung Zip Chemical Ind's conference presentation, Oct 16, 2025
Slide 1: 2025 Investors Conference
Stock Code ：4102 2025 Investors Conference Oct. 16, 2025
Slide 2: Disclaimer
Disclaimer This presentation and the forward-looking information mentioned in the simultaneously released related messages, including operational outlook, financial conditions, and business forecasts, are based on information obtained by the company from internal and external sources. The actual fut
Slide 3: Contents
CONTENTS Company Introduction Financial Performance Overview Business Development Research and Development Strategy 2/21
Slide 4: Company Introduction: Vision & Goals
Company Introduction: Vision & Goals Yung Zip Chemical Ind. Co., Ltd. established on June 8, 1978. As the first executor of GMP API certification in Taiwan, and with over 40 years of experience in the API industry, Yung Zip has successively passed international certifications such as FDA, MHRA, PMDA
Slide 5: Core Business
Core Business Drugs registration TDMF ：16 Speciality US DMF：18 APIs Chemical EU CEP：3 JP MF：3 Optoelectronics Synthesis Technique Other countries：16 Plastics GMP approved Small-scale Test Semiconductor TFDA：16 Pilot Plant U.S. FDA：5 Material JP PMDA：3 GMP Certificate CDMO Subsidiary-
Slide 6: 2018-2024 Consolidated Revenue
2018-2024 Consolidated Revenue (In Thousands of New Taiwan Dollars) 700000 600000 1,787 4,255 3,022 Speciality Chemical 500000 13,257 328,041 Export 400000 40,122 318,597 321,682 market 9,793 259,802 300000 289,528 CDMO 284,896 200000 271,259 122,879 119,976 91,988 106,057 Domestic market 79,937 37,
Slide 7: Corporate Resilience Strategy
Corporate Resilience Strategy Operational Resilience Financial Resilience Industry and Market Diversification Strategy Resilience Resilience Expand areas of Invest in Taiwan Way Deepen cultivation in Specialty chemicals: collaboration to expand into new Chein to build cross- APIs, continuous
Slide 8: Contents
CONTENTS Company Introduction Financial Performance Overview Business Development Research and Development Strategy 7/21
Slide 9: Statement of Consolidated Comprehensive Income
Statement of Consolidated Comprehensive Income Items 2024 H1 2025 H1 (In Thousands of New Taiwan Dollars) YoY (Reviewed) (Reviewed) Operating Revenue 324,788 256,212 -21% Operating costs 209,414 197,802 -6% Gross Profit 115,374 58,410 -49% Gross Margin 35% 23% Operating Expenses 58,559 56,736 -3% Op
Slide 10: Consolidated Balance Sheet
Consolidated Balance Sheet Items 2023/6/30 2024/6/30 2025/6/30 (In Thousands of New Taiwan Dollars) (Reviewed) (Reviewed) (Reviewed) Cash and Cash Equivalents 156,674 15% 171,303 17% 99,786 11% Receivables 120,299 12% 114,118 11% 79,860 8% Inventories 153,496 15% 158,433 15% 144,992 16% Long-term In
Slide 11: Statement of Consolidated Cash Flows
Statement of Consolidated Cash Flows 2023 H1 2024 H1 2025 H1 (In Thousands of New Taiwan Dollars) (Reviewed) (Reviewed) (Reviewed) Cash and cash equivalents at beginning of period 144,179 124,111 133,526 Cash flows from operating activities 58,979 83,204 4,353 Cash flows from investment activities (
Slide 12: Contents
CONTENTS Company Introduction Financial Performance Overview Business Development Research and Development Strategy 11/21
Slide 13: Jan.-Aug. Operating Revenue (2024 VS 2025)
Jan.-Aug. Operating Revenue (2024 VS 2025) Currency: one thousand NT dollars 500,000 446,788 450,000 Sales Distribution 400,000 192,536 (59%) 350,000 324,808 外銷 275,306 300,000 (62%) 250,000 (41%) 132,272 200,000 內銷 (38%) 171,482 150,000 - 50,000 100,000 150,000 200,000 250,000 300,000 100,000 Jan.
Slide 14: Globe Market distribution
Globe Market distribution Period: Jan. – Aug. of 2024/2025 JAN.–AUG. 2024 America JAN.–AUG. 2025 2% America Europe Europe 9% 3% Africa 4% Africa 1% Taiwan 1% Taiwan 38% 41% Asia Asia 52% 49% JAN.–AUG. 2024 JAN.–AUG. 2025 DIFFERENCE Taiwan 38% 41% 3% Asia 49% 52% 3% Africa 1% 1% 0% America 9% 2% -7%
Slide 15: Product Category Analysis
Product Category Analysis Period: Jan. – Aug. of 2024/2025 Currency: one thousand NT dollars 140,000 5% 34% 57% 120,000 100,000 80,000 60,000 40,000 29% 9% 20,000 0 Excipient Analgesic CMO & Antiseptic Other APIs Speciality Chemicals Jan.-Aug. 2024 Jan.-Aug. 2025 14/21
Slide 16: Industry Overview
Industry Overview GLOBE • The global Active Pharmaceutical Ingredients market is projected to reach USD 230–250 billion by 2025, with an average annual growth rate of around 6%. Driven by the rising prevalence of chronic diseases, population aging, and the demand for high value-added treatments, syn
Slide 17: Contents
CONTENTS Company Introduction Financial Performance Overview Business Development Research and Development Strategy 16/21
Slide 18: Research and Development Strategy
Research and Development Strategy Five Core Pillars Driving Innovation and Sustainable Growth In response to the increasingly fierce competition and sustainability challenges in the pharmaceutical industry, we have formulated five core R&D strategies aimed at enhancing our market competitiveness, in
Slide 19: Research and Development Project
Research and Development Project API *Global market *Global market Progress Product Indication scale scale (USD) (kg) SBT Heart failure treatment 10,440 M 271,216 EDV Amyotrophic lateral sclerosis 703 M 1,229 Process Validation MRG Overactive bladder 3,326 M 59,637 Completed ZPT Insomnia 592 M 33,
Slide 20: Research and Development Project
Research and Development Project Speciality Chemicals & Pharmaceutical Ingradients Quantity Progress Product Indication Area (KG/YEAR) TX06 Speciality chemical TW/JP 300 Process Development Completed TX07 Speciality chemical TW/JP 2,000 (Make-to-order period) TX08 Speciality chemical TW/JP 3,600~4
Slide 21: Thank you for your attention !
Thank you for your attention ! 20/21
Slide 22: Q&A
Ｑ&A 21/21